Clinical Trials Browser

Esophageal Neoplasms

NCT07472868 2026-03-16

MEND-IT II

Phase 3 Not yet recruiting

394 enrolled

Pathologic Complete Response

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Phase 1 Recruiting

30 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Active not recruiting

2 enrolled

Gastrointestinal

Colonic Neoplasms

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Phase 2 Completed

46 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT07070466 2026-03-06

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04230187 2026-03-05

TRIBE-C

Phase 3 Recruiting

528 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04683315 2026-03-05

PANCREAS

Phase 2 Recruiting

84 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

382 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04094688 2026-03-03

SOLARIS

Phase 3 Active not recruiting

455 enrolled 13 charts

Gastrointestinal

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

Phase 3 Recruiting

582 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Phase 4 Not yet recruiting

42 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07441369 2026-03-02

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

Phase 2 Enrolling by invitation

16 enrolled

Gastrointestinal

Liver Metastases From Colorectal Cancer (mCRC)

NCT07437287 2026-02-27

CROCOBIL

Phase 2/3 Not yet recruiting

160 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05567835 2026-02-23

TOGAR

Phase 2 Terminated

3 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06835387 2026-02-17

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Phase 2 Recruiting

36 enrolled

Gastrointestinal

Small Bowel Adenocarcinoma

Clinical Trials

PROTECT

MEND-IT II

Venetoclax Basket Trial for High Risk Hematologic Malignancies

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

TRIBE-C

PANCREAS

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

SOLARIS

FOBEAR

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

CROCOBIL

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

TOGAR

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors